ARGX vs BIIB stock comparison
Argenx vs. Biogen · data as of November 13, 2026
Argenx (ARGX) has a market value of about $59.6B, Biogen (BIIB) about $37.5B. Over their latest twelve months Argenx had revenue of $5.8B and Biogen $10.3B.
On our five checks Argenx scores higher: 2.4 out of 5 (weak) against 1.8 (weak).
By area, the stronger company is Biogen on value; Argenx on future growth; Argenx on track record; Argenx on financial health.
Argenx is cheaper on earnings (P/E 33.2 vs. 109.2).
Argenx leads on 12 of the compared lines and Biogen on 8.
Side by side
| ARGX | BIIB | |
|---|---|---|
| Size and price | ||
| Market cap | $59.6B | $37.5B |
| Share price | $960.04 | $253.40 |
| Score | ||
| Overall score (of 5) | 2.4 | 1.8 |
| Value | 0 | 1 |
| Future growth | 4 | 2 |
| Track record | 2 | 1 |
| Financial health | 5 | 4 |
| Shareholder returns | 1 | 1 |
| Valuation | ||
| P/E (TTM) | 33.2 | 109.2 |
| Forward P/E | 31.5 | 17.4 |
| Price / free cash flow | 193.0 | 18.1 |
| Price / sales | 10.2 | 3.6 |
| EV / EBITDA | 28.6 | 26.7 |
| PEG | — | — |
| DCF value vs. price | −72% | −33% |
| Business | ||
| Revenue | $5.8B | $10.3B |
| Net income | $1.9B | $348M |
| Free cash flow | $309M | $2.1B |
| Net margin | 32.2% | 3.4% |
| Gross margin (5-yr avg.) | 90.8% | 76.9% |
| ROIC (5-yr avg.) | -7.0% | 9.2% |
| Growth | ||
| Revenue growth (1 yr) | 88.6% | 2.2% |
| Revenue growth (5 yrs, per year) | 130.8% | -6.0% |
| EPS growth (5 yrs, per year) | — | -18.7% |
| Balance sheet and payouts | ||
| Net cash (cash minus debt) | $5.1B | -$6.1B |
| Dividend yield | None | None |
| Shareholder yield | 0.0% | 0.0% |
| Analysts | ||
| Upside to average target | +19% | +6% |
| Consensus rating | Buy | Buy |
Highlighted = the better figure on that line. Revenue, net income and free cash flow: ARGX TTM to September 30, 2026, BIIB TTM to September 30, 2026. Not investment advice.
Frequently asked questions
Which is the better stock, Argenx or Biogen?
We do not give buy or sell advice. On our five checks (value, growth, track record, financial health and shareholder returns) Argenx scores 2.4 out of 5 and Biogen 1.8; the table shows where each one is stronger.
Is Argenx cheaper than Biogen?
On trailing earnings, Argenx trades at a P/E of 33.2 and Biogen at 109.2, so Argenx is cheaper by this measure. A lower P/E can also reflect slower expected growth.
Which grows faster, Argenx or Biogen?
Over five years Argenx grew revenue about 130.8% a year and Biogen about -6.0% a year.
Full Argenx analysis → Full Biogen analysis →
More comparisons
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.